CBD trial challenges traditional antipsychotic for dual diagnosis
NCT ID NCT04105231
Summary
This study compares cannabidiol (CBD) with the antipsychotic medication risperidone for treating psychosis in people who have used cannabis. Researchers want to see if CBD can reduce psychotic symptoms and cannabis use while causing fewer side effects than standard treatment. The trial involves 64 adults aged 18-45 with psychosis and lifetime cannabis use.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUAL DIAGNOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Center for Neuropsychiatric Schizophrenia Research
Glostrup Municipality, 2600, Denmark
Conditions
Explore the condition pages connected to this study.